Jericho, New York, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental-stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, has engaged Strategic Investor Relations, LLC, a premier investor relations firm, to enhance Curanex’s visibility in the financial community and support its ongoing efforts to engage and educate current and potential investors about the Company’

Oct. 20, 2025 -- Adaptyx Biosciences, a biowearables company developing the first platform for continuous, multi-analyte molecular monitoring, today announced it has raised $14 million in seed financing, bringing total funding to $23 million since inception. The round was led by Interlagos, with significant participation from Overwater Ventures, and joined by Starbloom Capital, Stanford University, the Chan Zuckerberg Biohub, Hyperlink Ventures, Cantos Ventures, Humba Ventures, and Seaside Vent

On track to initiate TRX319 Phase 1/2a dose-escalation trial in early 2026 TRX319 is an allogeneic CAR-Tr1 Treg cell therapy designed to pair targeted B-cell control with active anti-inflammatory signaling and pathogenic T-cell modulation in a CNS-penetrant package $50 million in venture financing extends cash runway into 2027, allowing Tr1X to advance the TRX319 Phase 1/2a study and the ongoing TRX103 Phase 1/2a trial for patients with refractory Crohn’s disease Oct. 14, 2025 -- Tr1X, a clini

– Financing led by new investor Bain Capital Private Equity with participation from new and existing investors to support continued development of a differentiated, late-stage portfolio of obesity treatments – – Proceeds support advancement of KAI-9531, an injectable GLP-1/GIP dual agonist with potentially best-in-category weight loss, to global Phase 3 trials by year end – – Kailera continues to progress clinical development across its broader pipeline of oral and injectable obesity therapies –

EVerZom raises €10M to develop exosome-based biotherapies for inflammatory diseases Through this funding round, the company will initiate the clinical development of its first therapeutic candidate, EVerGel, in 2026, and will enhance its exosome biomanufacturing platform to advance its regenerative medicine programs. October 14th, 2025 – EVerZom, a French biotechnology company pioneering exosome-based therapies for regenerative medicine applications, today announced the closing of a €10 millio

Oct. 09, 2025 -- Children’s National Hospital and the Gilbert Family Foundation today announced a new $8 million, five-year grant to support groundbreaking research on neurofibromatosis type 1 (NF1). The grant, which is part of Gilbert Family Foundation’s Brain Tumor Initiative (BTI), will accelerate investigations aimed at improving the lives of children and young adults affected by this genetic condition. NF1 affects approximately 1 in 2,500 births each year. It causes potentially deadly ne

Oct. 07, 2025 -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $135 million to the Company, before placement agent fees and offering expenses. The PIPE financing included p

October 8, 2025 – Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), announced today that it has secured a EUR 1 million grant from Flanders Innovation & Entrepreneurship (VLAIO). Confo will use this 2-year grant to advance research and development of ultra-long-acting medicines targeting GPCRs, including bi- and multi-specific antibody formats, built on its proprietary, patent-protected platform. These next-generation antibody therape

Oct. 07, 2025 -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) (“Cellectar” or the “company”), a late-stage biotechnology company focused on the discovery and development of drugs for the treatment of cancer, today announced an agreement between the company and several institutional investors to exercise certain existing warrants (the “Existing Warrants”) for gross proceeds to the company of approximately $5.8 million prior to deducting placement agent fees and estimated offering expenses. Ladenb

Trogenix's breakthrough Odysseus® platform targets cancer cells to deliver precision therapies with curative “one and done” potential across multiple aggressive, treatment-resistant cancers Financing round led by IQ Capital with participation from founding investor 4BIO Capital, returning investors Cancer Research Horizons and the National Brain Tumor Society’s Brain Tumor Investment Fund, and new investors Eli Lilly and Company, Meltwind, LongeVC, and Calculus Capital Cancer Research Horizons’